Cell Therapeutics's CHOP-Zevalin Found Effective in Elderly Lymphoma Patients
Posted on: Thursday, 6 March 2008, 09:01 CST
Cell Therapeutics has reported encouraging results of a limited Phase II study of CHOP or cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy followed by Zevalin administration in elderly patients with previously untreated diffuse large B-cell lymphoma.
In this study, 20 previously untreated elderly patients were treated with a novel combination of six cycles of CHOP chemotherapy followed by Zevalin given six to ten weeks later. The study, which had an overall response rate of 100%, including a 95% complete remission rate, indicated the efficacy, tolerability, and feasibility of this regimen for these patients.
Jack Singer, chief medical officer of Cell Therapeutics, said: "Although a small Phase II experience, these results in elderly lymphoma patients treated with Zevalin following CHOP without rituximab demonstrate high rates of complete remissions and overall survival and are consistent with the potential to use Zevalin as consolidation therapy in aggressive lymphoma. We continue to be impressed with the high rate of conversion of partial to complete remissions following Zevalin consolidation irrespective of whether or not rituximab therapy is utilized."
Source: Datamonitor
Related Articles
- Allos Therapeutics Announces Interim Data From Phase 1 Study of PDX in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
- Allos Therapeutics Completes Patient Enrollment in Pivotal Phase 2 PROPEL Trial of PDX in Patients With Peripheral T-Cell Lymphoma
- ONTAK(R) (Denileukin Diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
- Cyclacel Pharmaceuticals Begins Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-Cell Lymphoma
- Journal of Clinical Oncology Publishes Final Study Results of VELCADE(R) (Bortezomib) for Injection in Relapsed Mantle Cell Lymphoma
- Allos' T-Cell Lymphoma Drug on Fast Track
- Allos Therapeutics Receives FDA Fast Track Designation for PDX for the Treatment of T-Cell Lymphoma
- Allos Therapeutics Initiates Pivotal Phase 2 Study of PDX in Patients With Peripheral T-Cell Lymphoma
- Allos Therapeutics Receives Special Protocol Assessment for Pivotal Phase 2 Study of the Company's Novel Antifolate PDX in Patients With Peripheral T-Cell Lymphoma
- Exercise Could Build Brain Cells in Elderly, Study Suggests
User Comments (0)
RSS Feeds